Post-stroke depression, antidepressant treatment and rehabilitation results: A case-control study

Stefano Paolucci, Gabriella Antonucci, Maria Grazia Grasso, Daniela Morelli, Elio Troisi, Paola Coiro, Domenico De Angelis, Francesco Rizzi, Maura Bragoni

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

The aim of this study was to assess the specific influence of poststroke depression (PSD) on both basal functional status and rehabilitation results. We performed a case-control study in 290 stroke inpatients, matched for age (±1 year) and onset admission interval (±3 days) and divided in two groups according to the presence (PSD+) or absence (PSD-) of PSD. All PSD +patients were treated with antidepressants (AD), mainly with fluoxetine. PSD + patients, despite similar severity of stroke, showed greater disability in coping with activities of daily living (ADL) on admission and greater disability both in ADL and mobility at discharge than PSD- patients. Although both groups exhibited similar average functional improvement during rehabilitation, PSD- patients were nearly twice as likely to show excellent recovery both on ADL and mobility as PSD +patients (OR =1.95, 95% CI =1.01-3.75 and OR =2.23, 95% CI =1.14-4.35, respectively). All AD drugs improved depressive symptoms. Few relevant side effects were observed: fluoxetine was discontinued in 2 patients because of insomnia and in 2 patients because of nausea; paroxetine was stopped in 1 patient because of nausea and dry mouth. Our results confirm the unfavorable influence of PSD on functional outcome, despite pharmacological treatment.

Original languageEnglish
Pages (from-to)264-271
Number of pages8
JournalCerebrovascular Diseases
Volume12
Issue number3
DOIs
Publication statusPublished - 2001

Fingerprint

Antidepressive Agents
Case-Control Studies
Rehabilitation
Stroke
Depression
Activities of Daily Living
Therapeutics
Fluoxetine
Nausea
Paroxetine
Sleep Initiation and Maintenance Disorders
Mouth
Inpatients
Pharmacology

Keywords

  • Antidepressive agents
  • Cerebrovascular disorders
  • Depression
  • Rehabilitation

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Post-stroke depression, antidepressant treatment and rehabilitation results : A case-control study. / Paolucci, Stefano; Antonucci, Gabriella; Grasso, Maria Grazia; Morelli, Daniela; Troisi, Elio; Coiro, Paola; De Angelis, Domenico; Rizzi, Francesco; Bragoni, Maura.

In: Cerebrovascular Diseases, Vol. 12, No. 3, 2001, p. 264-271.

Research output: Contribution to journalArticle

Paolucci, Stefano ; Antonucci, Gabriella ; Grasso, Maria Grazia ; Morelli, Daniela ; Troisi, Elio ; Coiro, Paola ; De Angelis, Domenico ; Rizzi, Francesco ; Bragoni, Maura. / Post-stroke depression, antidepressant treatment and rehabilitation results : A case-control study. In: Cerebrovascular Diseases. 2001 ; Vol. 12, No. 3. pp. 264-271.
@article{0fa06e4c7944476baa2ba38e094f3917,
title = "Post-stroke depression, antidepressant treatment and rehabilitation results: A case-control study",
abstract = "The aim of this study was to assess the specific influence of poststroke depression (PSD) on both basal functional status and rehabilitation results. We performed a case-control study in 290 stroke inpatients, matched for age (±1 year) and onset admission interval (±3 days) and divided in two groups according to the presence (PSD+) or absence (PSD-) of PSD. All PSD +patients were treated with antidepressants (AD), mainly with fluoxetine. PSD + patients, despite similar severity of stroke, showed greater disability in coping with activities of daily living (ADL) on admission and greater disability both in ADL and mobility at discharge than PSD- patients. Although both groups exhibited similar average functional improvement during rehabilitation, PSD- patients were nearly twice as likely to show excellent recovery both on ADL and mobility as PSD +patients (OR =1.95, 95{\%} CI =1.01-3.75 and OR =2.23, 95{\%} CI =1.14-4.35, respectively). All AD drugs improved depressive symptoms. Few relevant side effects were observed: fluoxetine was discontinued in 2 patients because of insomnia and in 2 patients because of nausea; paroxetine was stopped in 1 patient because of nausea and dry mouth. Our results confirm the unfavorable influence of PSD on functional outcome, despite pharmacological treatment.",
keywords = "Antidepressive agents, Cerebrovascular disorders, Depression, Rehabilitation",
author = "Stefano Paolucci and Gabriella Antonucci and Grasso, {Maria Grazia} and Daniela Morelli and Elio Troisi and Paola Coiro and {De Angelis}, Domenico and Francesco Rizzi and Maura Bragoni",
year = "2001",
doi = "10.1159/000047714",
language = "English",
volume = "12",
pages = "264--271",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Post-stroke depression, antidepressant treatment and rehabilitation results

T2 - A case-control study

AU - Paolucci, Stefano

AU - Antonucci, Gabriella

AU - Grasso, Maria Grazia

AU - Morelli, Daniela

AU - Troisi, Elio

AU - Coiro, Paola

AU - De Angelis, Domenico

AU - Rizzi, Francesco

AU - Bragoni, Maura

PY - 2001

Y1 - 2001

N2 - The aim of this study was to assess the specific influence of poststroke depression (PSD) on both basal functional status and rehabilitation results. We performed a case-control study in 290 stroke inpatients, matched for age (±1 year) and onset admission interval (±3 days) and divided in two groups according to the presence (PSD+) or absence (PSD-) of PSD. All PSD +patients were treated with antidepressants (AD), mainly with fluoxetine. PSD + patients, despite similar severity of stroke, showed greater disability in coping with activities of daily living (ADL) on admission and greater disability both in ADL and mobility at discharge than PSD- patients. Although both groups exhibited similar average functional improvement during rehabilitation, PSD- patients were nearly twice as likely to show excellent recovery both on ADL and mobility as PSD +patients (OR =1.95, 95% CI =1.01-3.75 and OR =2.23, 95% CI =1.14-4.35, respectively). All AD drugs improved depressive symptoms. Few relevant side effects were observed: fluoxetine was discontinued in 2 patients because of insomnia and in 2 patients because of nausea; paroxetine was stopped in 1 patient because of nausea and dry mouth. Our results confirm the unfavorable influence of PSD on functional outcome, despite pharmacological treatment.

AB - The aim of this study was to assess the specific influence of poststroke depression (PSD) on both basal functional status and rehabilitation results. We performed a case-control study in 290 stroke inpatients, matched for age (±1 year) and onset admission interval (±3 days) and divided in two groups according to the presence (PSD+) or absence (PSD-) of PSD. All PSD +patients were treated with antidepressants (AD), mainly with fluoxetine. PSD + patients, despite similar severity of stroke, showed greater disability in coping with activities of daily living (ADL) on admission and greater disability both in ADL and mobility at discharge than PSD- patients. Although both groups exhibited similar average functional improvement during rehabilitation, PSD- patients were nearly twice as likely to show excellent recovery both on ADL and mobility as PSD +patients (OR =1.95, 95% CI =1.01-3.75 and OR =2.23, 95% CI =1.14-4.35, respectively). All AD drugs improved depressive symptoms. Few relevant side effects were observed: fluoxetine was discontinued in 2 patients because of insomnia and in 2 patients because of nausea; paroxetine was stopped in 1 patient because of nausea and dry mouth. Our results confirm the unfavorable influence of PSD on functional outcome, despite pharmacological treatment.

KW - Antidepressive agents

KW - Cerebrovascular disorders

KW - Depression

KW - Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=0034775115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034775115&partnerID=8YFLogxK

U2 - 10.1159/000047714

DO - 10.1159/000047714

M3 - Article

C2 - 11641594

AN - SCOPUS:0034775115

VL - 12

SP - 264

EP - 271

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 3

ER -